参考文献
[1] Ejerblad E,Fored CM,Lindblad P,et al.Association betwecn smoking and chronic renal failure in a nation-wide population-based case-control study.J Am Soc Nephrol,2004,15:2178-2185.
[2] Rabbal CG.Review:alow-protein diet delays end-stage renal disease or death in stage 3to 5chronic kidney disease.ACP J Club,2006,145:64.
[3] Zeller K,Whittaker E,Sullivan L,et al.Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus.N Engl J Med,1991.
[4] 谢红浪,季大玺,龚德华,等.低蛋白饮食治疗早期慢性肾功能不全的临床观察.肾脏病与透析肾移植杂志,2006,15:422-427.
[5] Levey AS,Greene T,Sarnak MJ,et al.Effecl of dietary protein restriction on the progression of kidney disease:long-term follow-up of the modification of Diet in Renal disease(MDRD)Study.Am J Kidney Dis,2006,48:879-888.
[6] Teixeira SR,Tappenden KA,Carson L,et al.Isolated soy protein consumption reduces urinary albumin excretion and irnproves the serum lipid profile in men with type 2diabetes mellitus and nephropathy.J Nutr,2004,134:1874-1880.
[7] Kinchen KS,Sadler J,Fink N,et al.The timing of Specialist Evaluation in Chronic Kidney Disease and Mortality.Ann Intern Med,2002,137:479-486.
[8] Savica V,Calvani M,Benatti P,et al.Newer aspects of carnitine metabolism in uremia.Semin Nephrol,2006,26:52-55.
[9] Klahr S,Levey AS,Beck GJ,et al.The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease.Modification of Diet in Renal Disease Study Group.N Engl J Med,1994,330:877-884.
[10] Ruggenenti P,Perna A,Loriga G,et al.Blood-pressure control for renopre-tection in patients with non-diabetic chronic renal disease[REIN-2]:multicentre,randomised controlled trial.Lancet,2005,365:939-946.
[11] Gouva C,Nikolopoulos P,loannidis JP,et al.Treating anemia early in renal failure patients slows the decline of renal function:a randomized controlled trial.Kidney Int,2004,66:753-760.
[12] Schwarz C,Sulzbacher I,Oberbauer R.Diagnosis of renal osteodystrophy.Fur I Clin Invest,2006,36(Suppl)2:13-22.
[13] Moe S,Drueke T,Cunningham J,et al.Definition,evaluation,and classificatipn of renal osteodystrophy:aposition statement from Kidney Disease:Improving Global Outcomes(KDIGO).Kidney Int,2006,69:1945-1953.
[14] Bailey JL.Metabolic acidosis:an unrecognized cause of morbidity in the patient with chronic kidney disease.Kidney Int,2005,68(suppl 96):S15-S23.
[15] Chen X,Qiu Q,Tang L,et al.Effects of co-administralion of urokinase and benazepril on severe IgA nephropathy.Nephrol Dial Transplant,2004,19:852-857.
[16] 陈香美,廖洪军,李宁虹,等.慢性肾功能衰竭大鼠IL-2基因表达的改变及淫羊藿的调节作用.解放军医学杂志,1995,20:353-354.
[17] Abel JJ,Rowntree LG,Turner BB.On the removal of diffusible substances from circulating blood by means of dialysis.Trans Ass Amer Physicisns,2003,28:51.
[18] Schulman G,Himmelfarb J.Hemodialysis/Brenner,Rector.The Kidney.7th ed.Philadelphia;Saunders,2004:2563-2567.
[19] Almaden Y,Canalejo A,Ballesteros E,et al.Effect of high extracellular phosphate concentration on arachidonic acid production by parathyroid tissue in vitro.J Am Soc Nephrol,2000,11:1712-1718.
[20] Taal MW,Roe S,Masud T,et al.Total hip bone mass predicts survival in chronic hemodialysis patients.Kidney Int,2003,63:1116-1120.
[21] Patel SR,Ke HQ,Vanholder R,et al.Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins.J Clin Invest,1995,96:50-59.
[22] Cogusev J,Duchambon P,Hory B,et al.Depressed expression of calciumreceptor in parathyroid gland tissue of patients with hyperparathyroidism.Kidney Int,1997,51:328-336.
[23] Mizobuchi M,Hatamura I,Ogala H,et al.Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.J Am Soc Nephrol,2004,25:2579-2587.
[24] Cozzolino M,Lu Y,Finch J,et al.p21WAFI and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.Kidney Int,2001,60:2109-2117.
[25] Iwasaki Y,Yamaw H,Nii-Kono T,et al.Insufficiency of PTH action on hone in uremia.Kidney Int,2006,Suppl 102:S34-S36.
[26] Panda DK,Miao D,Bolivar I,et al.inactivation of the 25-hydroxyvitamin D-ialpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and minaeral homeostasis.J Biol Chem,2004,279:16754-16766.
[27] Friedman PA,Goodman WG.PTH(1-84)/PTH(7-84)a balance of power.Am J Physiol Renal Physiol,2006,290:F975-F894.
[28] Hoyland JA,Picton ML.Cellular mechanisms of renal osteodytrophy.Kidney Int,1999,Suppl 56:S8-S13.
[29] Lund RJ,Davies MR,Brown AJ,et al.Successful treat ment of an adynamic bone disorder in chronic kidney disease with hone morphogenetic protein-7.J Am Soc Nephrol,2004,15:359-369.(https://www.daowen.com)
[30] 季大玺,谢红浪,陈惠萍,等.维持性血液透析患者肾性骨病的相关因素分析.肾脏病与透析肾移植杂志,2000,9.113-117.
[31] Souberbielle JC,Boutten A.Carlier MC,et al.Intermethod variability in PTH measurement:implication for the care of CKD patients.Kidney lnt,2006,70:345-350.
[32] Neves KR,Graciolli FG,Dos Reis LM,et al.Vascular calcification:contribution of parathyroid hormone in renal failure.Kidney lnt,2007,71:1262-1270.
[33] 王海燕,王梅,主译.慢性肾脏病及透析的临床实践指南Ⅱ.北京:人民卫生出版社,2005:303-422.
[34] Bervoets AR,Spasovski GB,Behets GJ,et al.useful biochemical mark-ers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients.A m J Kidney Dis,2003,41:997-1007.
[35] 刘铁滨,王维.长期血液透析患者腰椎骨密度定量CT的监测及意义.实用放射学杂志,2004,20:1104-1106.
[36] Kavesdy CP,Mehrotra R,Kalantar-Zadeh K.Battle-ground:chronic kidney disorders mineral and bone disease-calcium obsession,vitamin D,and binder confusion.Clin J Am Soc Nephrol,2008,3:168-173.
[37] Yumita S.Impact of sevelamer hydrochloride and the K/DOQJ guidelines.Ther Apher Dial,2005,9(uppl 1):S7-S10.
[38] Albaaj F,Hutchison AJ.Lanthanum carbonate for the reatment of hyperphosphataemia in renal failure and dialysis patients.Expert Opin Pharmacother,2005,6:319-328.
[39] Hemandez JD,Wcsseling K,Salusky IB.Role of parathyroid hormone and therapy wilh active vitamin D sterols in renal osteodystrophy.Semin Dial,2005,18:290-295.
[40] Goodman WG.Calcimimetic agents and secondary hyperparathyroidism:rationale for using results from clinical trials.Pediatr Nephrol,2003,18:1206-1210.
[41] Wada M.Nagano N.Control of parathyroid cell growth by calcimimetics.Nephrol Dial Transplant,2003,18(Suppl 3):iii13-iii17.
[42] Wada M,lshii H,Furuya Y,et al.NPS R-568halts or reverses osteitis fibrosa in uremic rats.Kidney Int,1998,53:448-453.
[43] Miller MA,Fox J.Daily transient decreases in plasma parathyroid hormone levels induced by the calcimimetic NPS R-568slows the rate of bone loss but dose not increase bone mass in ovariectomized rats.Bone,2002,27:511-519.
[44] Brown AJ.Thcrapeutic uses of vitamin D analogues.Am J Kidney Dis,2001,38(Suppl):S3-S19.
[45] Seibert E,Levin NW,Kuhlmann MK.Immunomodulating effects of vitamin D analogs in hemodialysis patients.Hemodial Inl,2005,9(Suppl 1):S25-S29.
[46] Makibayashi K,Tatematsu M,Hirata M,et al.A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis.Am J Pathol,2001,158:1733-1741.
[47] Salusky IB.Are new vitamin D analogues in renal bone disease superior la calcitriol?Pediatr Nephrol,2005,20:393-398.
[48] Kotzmann H,Riedl M,Pietschmann P,et al.Effects of 12months of recombinant hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.J Nephrol,2004,17:87-94.
[49] Li T,Surendran K,Zawaideh MA,et al.Bone morphogenetic protein 7:a novel treatment for chronic renal and bone disease.Curr Opin Nephrol Hypertens,2004,13:417-422.
[50] Lund RJ,Davies MR,Braw AJ,et al.Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7in renal ablation model.J Am Soc Nephrol,2004,15:359-369.
[51] 龚德华,季大玺、陈惠萍,等.高通量维持性血液透析患者甲状旁腺素水平及骨代谢的变化.肾脏病与透析肾移植杂志,2001,10:317-321.
[52] Toussaint ND,Polkinghome KR,Kerr PG,et al.Comparison between different dialysate calcium cuncentrations in nocturnal hemodialysis.Hemodial Int,2007,11:217-224.
[53] 张炯,俞雨生.低钙腹膜透析液对肾性骨病的影响.肾脏病与透析肾移植杂志,2006,15:278-281.
[54] 罗洋,张凌,卞维静,等.经皮乙醇注射治疗血液透析继发甲状旁腺功能亢进症远期预后研究.中日友好医院学报,2007,21:333-348.
[55] Shiizaki K,Hatamura 1,Negi S,et al.Percutaneous Maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia.Kidney Int,2007,71:992-1003.
[56] 胡建明,吴宏飞,王笑云,等.肾性甲状旁腺功能亢进症甲状旁腺全切加前臂移植31例临床分析.中华内科杂志,2006,45:714-716.
